The Effects of D-Fagomine on Glycaemic Response to Sucrose in Men
NCT ID: NCT01528631
Last Updated: 2012-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
12 participants
INTERVENTIONAL
2012-02-29
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control Product
200 ml water with 50g of sucrose
D-Fagomine
0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
Product 1
200 ml water with 50g of sucrose and supplemented with 30 mg of D-Fagomine
D-Fagomine
30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-Fagomine
30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
D-Fagomine
0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Triglycerides higher than 350 mg/dl (the threshold level to determine c-LDL using the Friedewald formula)
3. Physical examinations and routine biochemical analysis shall be conducted to rule out pathologies.
4. Consumption of supplements or acetylsalicylic acid
5. Chronic alcoholism
6. Body mass index (BMI) greater than 30 kg/m2
7. Previous antihypertensive treatment at the start of the trial that has not finished at least 2 months before beginning the study
8. Diabetes mellitus (if the fasting blood glucose is higher than 126 mg/dl, the test should be repeated and confirmed)
9. Kidney disease (serum creatine levels above 1,4 mg/dl for women and above 1,5 mg/dl for men)
10. Acute infectious diseases, malignant tumors, severe liver failure, respiratory failure associated with chronic or endocrine diseases
11. Other conditions such as special dietary needs
12. To be participating or having participated in a clinical trial within the last 3 months
13. Inability to continue the study
14. History of gastrointestinal disease which may alter the absorption of nutrients
15. Depressive disorder or thoughts of self-injury
20 Years
70 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Rovira i Virgili
OTHER
Technological Centre of Nutrition and Health
OTHER
National Research Council, Spain
OTHER_GOV
Bioglane
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rosa Solà, PhD MD
Role: PRINCIPAL_INVESTIGATOR
University Rovira i Virgili
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Universitari Sant Joan, Universitat Rovira i Virgili
Reus, Tarragona, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gomez L, Molinar-Toribio E, Calvo-Torras MA, Adelantado C, Juan ME, Planas JM, Canas X, Lozano C, Pumarola S, Clapes P, Torres JL. D-Fagomine lowers postprandial blood glucose and modulates bacterial adhesion. Br J Nutr. 2012 Jun;107(12):1739-46. doi: 10.1017/S0007114511005009. Epub 2011 Oct 3.
Related Links
Access external resources that provide additional context or updates about the study.
BIOGLANE SLNE
D-Fagomine
CTNS - Technology Centre of Nutrition and Health
URV - Rovira i Virgili University
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1AP029010911
Identifier Type: -
Identifier Source: org_study_id